Search Bar & Filters
Found 14 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of orforglipron in adult women with stress urinary incontinence SUI who are overweight or have obesity. SUI is characterized by leaking urine during activities such as coughing or exercising. This phase 3 study aims to compare orforglipron to a placebo in this specific population. Participants will be randomly assigned to receive either orforglipron or a placebo orally. The study follows a parallel design with double masking and includes two independent groups. Treatment and assessments will occur over approximately 58 weeks, including screening, treatment, and safety follow-up. During the trial, participants will undergo evaluations to measure changes in the frequency of incontinence episodes, body weight, quality of life specific to urinary incontinence, use of continence pads, patient impression of condition, cholesterol levels, and waist circumference from baseline to week 52. Safety monitoring will continue through the follow-up period to assess any treatment-related effects.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in treating cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3 study is randomized, double-blind, and placebo-controlled, aiming to improve thinking abilities measured by specific standardized assessments. Participants will receive either KarXT plus KarX-EC or a placebo at specified doses on designated days. The study lasts 24 weeks, during which outcomes like changes in cognitive function, daily living activities, and behavioral symptoms will be assessed. The trial includes an active comparison group and a placebo group to evaluate treatment effects. Throughout the study, participants and their caregivers will attend regular visits for clinical assessments, including cognitive tests ADAS-Cog11, caregiver interviews, and monitoring of adverse events and vital signs. Researchers will carefully track safety and treatment response over the 24-week period to understand the impact of the study drugs on Alzheimers symptoms.
Actively Recruiting
Researchers are evaluating the safety and effects of a study medicine called PF-07328948 for treating adults with heart failure. This phase 2 clinical trial compares PF-07328948 to a placebo in people who are already receiving standard heart failure treatments, including sodium-glucose cotransporter 2 SGLT2 inhibitors. The study aims to determine if PF-07328948 is safe and effective for heart failure patients with specific symptoms and heart function measurements. Participants will take either PF-07328948 tablets or placebo tablets once daily by mouth for 36 weeks. There are four groups placebo, low dose, medium dose, and high dose of PF-07328948. The trial uses a randomized, double-blind design. During the study, participants will continue their regular heart failure medications alongside the study drug or placebo. Participants will be involved for about 48 weeks, including 36 weeks of treatment and follow-up. They will have 15 visits to the study clinic, with 10 visits in person and 5 conducted at home by phone. Assessments include clinical event tracking, 6-minute walk tests, and questionnaires to evaluate symptoms and physical limitations. Safety monitoring and health status questionnaires will be performed throughout the study.
Actively Recruiting
Researchers are studying how well tilrekimig works and how safe it is when combined with medicated creams or ointments in adults and adolescents aged 12 years or older who have moderate to severe atopic dermatitis, also known as eczema. This common skin condition causes dry, itchy, red, and irritated skin. The study focuses on participants who have had atopic dermatitis for at least 12 months and have not responded well to standard topical treatments. Participants will be randomly assigned in a 21 ratio to receive either tilrekimig or a placebo through subcutaneous injections over a 20-week period. The study treatment period lasts 24 weeks, with the last dose given at week 20. After completing this phase, some participants may join a long-term extension study to continue monitoring the effects and safety of tilrekimig, while others will enter a 12-week safety follow-up ending 16 weeks after their last dose. During the study, participants will be monitored closely with evaluations including eczema severity assessments, quality of life questionnaires, and safety checks such as vital signs and laboratory tests. Researchers will measure outcomes like the proportion of participants showing improvement in eczema severity at week 16. The total participation time includes the treatment period and follow-up, lasting several months to assess both short-term and longer-term effects of the study medicine.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.
Actively Recruiting
Researchers are evaluating the drug YMI024 in adults with stable coronary artery disease CAD who have persistent inflammation, indicated by high levels of high-sensitivity C-reactive protein hsCRP. This Phase 2b study aims to assess how well different doses of YMI024 reduce systemic inflammation, as well as to monitor the drugs safety, tolerability, and dose response compared to a placebo. Participants include those with CAD alone or CAD combined with heart failure or chronic kidney disease, and the study is designed to provide detailed subgroup analysis. Participants are randomly assigned to one of six groups in equal proportions, receiving one of five different doses of YMI024 or a matching placebo. All participants continue their stable standard-of-care therapies throughout the trial. The study is double-blinded, meaning neither the participants nor the study staff know who receives which treatment. Treatment is given alongside regular care, and dose effects and safety are assessed over approximately three months. During the study, participants will have their inflammatory markers, specifically IL-6 and hsCRP, measured at the start and around three months later to evaluate changes. Safety is monitored by tracking adverse events over about four months. Participants will undergo scheduled visits for assessments, including blood tests and clinical evaluations, while continuing their usual medical care. The total participation duration aligns with the treatment and follow-up periods to comprehensively assess both efficacy and safety.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Researchers are evaluating the effect and safety of orforglipron taken once daily in adults with Fontaine Stage II peripheral arterial disease PAD, a condition that causes symptoms like leg pain due to poor blood flow. The study is a phase 3 randomized, double-blind, placebo-controlled trial aiming to better understand how this treatment impacts walking ability and quality of life in this population. Participation is expected to last about 58 weeks. Participants are randomly assigned to receive either orforglipron or a placebo, both taken orally once daily. The study compares these two groups to assess changes in walking distances and other health measures over the course of the trial. This design helps evaluate the medications effect compared to no active treatment. During the study, participants undergo assessments including measuring maximum and pain-free walking distances, vascular quality of life via questionnaire, the six-minute walk test, blood markers like high-sensitivity C-reactive protein, and systolic blood pressure. These measurements occur at the start and after 52 weeks of treatment. Safety and effectiveness are monitored throughout, with overall participation lasting nearly a year.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of dupilumab in adults with chronic pruritus of unknown origin CPUO, a condition causing severe itching without a clear cause. This Phase 3 study includes two parallel, double-blind clinical trials involving men and women aged 18 to 90 years who have experienced severe itching for at least six months. The trials aim to compare dupilumab with a placebo while both groups also use a non-sedative antihistamine and moisturizer. After up to a 4-week screening, participants with severe itch enter a 4-week run-in period receiving antihistamines and moisturizers. Those still experiencing severe itching are randomly assigned to receive either dupilumab or placebo injections subcutaneously every two weeks for 24 weeks, alongside their existing treatments. Following this, all participants enter a 12-week follow-up period to monitor outcomes. Participants attend regular visits for assessments including itch severity ratings, quality of life questionnaires, and anxiety and depression scales. Researchers will measure changes in itch intensity, sleep disturbance, and life quality over time. Safety is closely monitored throughout the treatment and follow-up periods, with the total participation lasting up to 44 weeks.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of surgical aortic valve replacement SAVR compared to transcatheter aortic valve replacement TAVR in patients with isolated severe, calcific aortic stenosis who have a low risk for surgery. This randomized, controlled, multi-center study aims to show that SAVR is not worse than TAVR by measuring combined outcomes like death, stroke, and rehospitalization one year after the procedure. The study is sponsored by Osaka University and includes long-term follow-up for up to 10 years. Participants will be randomly assigned to receive either SAVR or TAVR using commercially available bioprosthetic valves. SAVR involves surgery with a choice of surgical bioprostheses and access methods based on the surgeons preference. TAVR is performed using devices available in approved Japanese facilities. Follow-up visits occur at hospital discharge, 30 days, and annually for up to 10 years to monitor outcomes and safety. During the study, participants will undergo evaluations including clinical assessments, imaging, and monitoring for events such as death, stroke, rehospitalization, valve function, bleeding, and quality of life, assessed by validated questionnaires. The main outcome is a composite of death from any cause, all stroke, and rehospitalization related to valve or procedure within one year. Safety and valve-related complications will also be tracked throughout the follow-up period. Participation may last up to 15 years, including long-term monitoring after the initial treatment.
1-10 of 14
1